INCA NETInfo
INCA GLOBAL NET PATIENT INFO PACK NEW FOR 2020! - NETInfo INCA launches a range of factsheets on NETs that are free to download. These factsheets provide [...]
LUTATHERA® Funded in Ontario
Radiopharmaceutical cancer treatment Lutathera® now available to Ontario patients with midgut neuroendocrine tumours (NETs). The Ontario funding criteria covers the treatment of adult patients with somatostatin receptor-positive (SSR+) midgut NETs [...]
LUTATHERA® Funded in Quebec
As of September 30, 2020, the Québec Ministry of Health and Social Services has listed Lutathera on the Liste de Médicaments – Établissements. Lutathera will be reimbursed for GEP-NETs patients [...]
LUTATHERA® Funded in Nova Scotia
As of August 1, 2020, patients with midgut, GEP-NETs will now be eligible for treatment with LUTATHERA® [lutetium (177Lu) oxodotreotide]. This listing covers adult patients with somatostatin receptor-positive (SSR+) midgut [...]
#HoofingIt launches at Peggy’s Cove July 1
HOOFING IT - The summer-long fundraiser launched at Peggy's Cove on July 1st. Sharon Needham, lung neuroendocrine cancer survivor and advocate; family, friends, supporters kicked-off HOOFING IT with a [...]
#HoofingIt fundraiser launches at Peggy’s Cove July 1
#HoofingIt across Canada to fight one of the fastest-growing class of cancers Canadian Neuroendocrine Tumour Society (CNETS) launches fundraising challenge at Peggy’s Cove July 1, 2020 HALIFAX [...]
Health Canada Approval of NETSPOT®
Advanced Accelerator Applications Announces Health Canada Approval of NETSPOT® Diagnostic Imaging Agent Kit to Detect Neuroendocrine Tumours NETSPOT® is the first and only kit for the preparation of [...]
New Delivery System for Somatuline® Autogel®
Ipsen Announces the Availability of the Newly Designed Delivery System for Somatuline® Autogel® (lanreotide injection) Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for [...]